Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Q: What sector and industry does Coherus BioSciences (CHRS) operate in?

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Open	$2.020
Close	$2.070
Volume / Avg.	2.880M / 3.298M
Day Range	1.950 - 2.090
52 Wk Range	1.430 - 8.340
Market Cap	$231.537M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	36
Short Interest	24.17%
Days to Cover	8.01

Recent News

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2. CommScope shares dipped 6.9% to $2.2150 on Monday.

Avi Kapoor

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.

Vandana Singh

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trend

Oct 23

Nov 23

Dec 23

Jan

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About Coherus Biosciences Inc

Sector

Health Care

Industry

Biotechnology

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Coherus BioSciences (CHRS) stock?

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Who are Coherus BioSciences's (CHRS) competitors?

Other companies in Coherus BioSciences’s space includes: Galectin Therapeutics (NASDAQ:GALT), Adverum Biotechnologies (NASDAQ:ADVM), Inovio Pharmaceuticals (NASDAQ:INO), Adaptimmune Therapeutics (NASDAQ:ADAP) and Abeona Therapeutics (NASDAQ:ABEO).

What is the target price for Coherus BioSciences (CHRS) stock?

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by HC Wainwright & Co. on Wednesday, March 20, 2024. The analyst firm set a price target for 11.00 expecting CHRS to rise to within 12 months (a possible 439.22% upside). 25 analyst firms have reported ratings in the last year.

Current Stock Price for Coherus BioSciences (CHRS)?

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $2.04 last updated Today at April 19, 2024 at 4:14 PM EDT.

Does Coherus BioSciences (CHRS) pay a dividend?

There are no upcoming dividends for Coherus BioSciences.

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

Coherus BioSciences’s Q1 earnings are confirmed for Monday, May 6, 2024.

Is Coherus BioSciences (CHRS) going to split?

There is no upcoming split for Coherus BioSciences.

What sector and industry does Coherus BioSciences (CHRS) operate in?

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-